Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,210
+440 (2.79%)
Nov 20, 2025, 3:30 PM KST
2.79%
Market Cap700.93B
Revenue (ttm)46.65B
Net Income (ttm)16.75B
Shares Out44.45M
EPS (ttm)n/a
PE Ratio41.84
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,742,787
Average Volume2,842,598
Open15,900
Previous Close15,770
Day's Range15,500 - 16,620
52-Week Range3,138 - 26,600
Betan/a
RSI56.30
Earnings DateNov 11, 2025

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.